Lansoprazolo Tecnimede (Lansoprazole)

Lansoprazole is indicated for several acid‑related gastrointestinal conditions.

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and prevents esophageal damage by reducing acid exposure.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a low‑acid environment.
• Helicobacter pylori eradication: used in combination regimens to increase bacterial eradication rates.
• Erosive esophagitis: heals mucosal injury and reduces symptoms through sustained acid suppression.

• Lansoprazole selectively and irreversibly inhibits the gastric H+/K+‑ATPase pump located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, leading to an increased gastric pH and allowing healing of acid‑mediated lesions. The effect persists for up to 72 hours after a single dose, providing prolonged acid control.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild, transient headache.
• Diarrhea: loose stools, usually self‑limiting.
• Nausea: mild nausea or stomach discomfort.
• Abdominal pain: crampy discomfort in the abdomen.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis requiring medical attention.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.
• Hypomagnesemia: low magnesium levels causing muscle cramps or arrhythmias.
• Stevens‑Johnson syndrome: severe skin reactions with blistering.
• Liver enzyme elevation: significant increase in hepatic transaminases.

When prescribing or dispensing lansoprazole, several safety considerations should be observed.

• Assess renal function: dose adjustment may be needed in severe renal impairment.
• Review concomitant medications: avoid use with drugs requiring acidic gastric pH for absorption.
• Monitor long‑term use: prolonged therapy may increase risk of fractures or vitamin B12 deficiency.
• Use caution in pregnancy: benefits should outweigh potential risks; consult obstetric guidance.
• Discontinue before surgery: consider stopping before procedures requiring gastric acidity.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid)

• Ketoconazole: reduced absorption leading to therapeutic failure.
• Atazanavir: decreased plasma levels compromising antiviral efficacy.
• Iron salts: diminished iron uptake causing anemia risk.
• Mycophenolate mofetil: lowered exposure may reduce immunosuppression.
• Warfarin: enhanced anticoagulant effect increasing bleeding risk.

Moderate Interactions (Monitor Closely)

• Digoxin: increased serum concentration, monitor levels.
• Methotrexate: possible accumulation, watch for toxicity.
• Clopidogrel: reduced activation, may lessen antiplatelet effect.
• Phenytoin: altered metabolism, monitor seizure control.
• Calcium carbonate: may affect absorption of both agents.